Home/Pipeline/APVO452

APVO452

Prostate Cancer

DiscoveryActive

Key Facts

Indication

Prostate Cancer

Phase

Discovery

Status

Active

Company

Aptevo Therapeutics

About Aptevo Therapeutics

Aptevo Therapeutics is a Seattle-based biotech focused on developing next-generation, multi-specific antibody therapies for cancer. The company's core strategy is its proprietary protein engineering platform, which enables the rational design of T-cell engagers and co-stimulatory molecules with tunable properties to potentially overcome limitations of current immunotherapies. Its most advanced asset, mipletamig (APVO436), is a CD3xCD123 bispecific in Phase 1/2 development for acute myeloid leukemia (AML). Operating as a lean, publicly-traded entity, Aptevo aims to advance its broad, early-stage pipeline through clinical validation and strategic partnerships.

View full company profile

Therapeutic Areas

Oncology Hematologic Cancer Solid Tumors

Other Prostate Cancer Drugs

Drug	Company	Phase	Status
APVO442	Aptevo Therapeutics	Preclinical	Active
BIO 300	Humanetics Corp.	Not Specified	Active
Opaganib	RedHill Biopharma	Phase 2	Active
MagSense™ PSMA Imaging Agent	Imagion Biosystems	Pre‑clinical	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
Leronlimab	CytoDyn	Preclinical	Phase in progress
CROES Registry	AngioDynamics	Post-Market Registry	Active
Cannabics® PRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC
HDP-103	Heidelberg Pharma	Preclinical	Active
ENV105	Kairos Pharma	Phase 2	Active
AI for Prostate Cancer	Invenio Imaging	Research	Active
Mitomic™ Test for Prostate Cancer	MDNA Life Sciences	Development/Validation	Active